がん免疫療法の市場規模、シェア、動向分析レポート：製品別、用途別、流通別、最終用途別、地域別、セグメント別予測、2024年～2030年

がん免疫療法市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のがん免疫療法市場規模は、2024年から2030年にかけて8.3％のCAGRを記録し、2030年までに2,243億米ドルに達すると予測されています。

その標的作用により、がんに対する他の治療法よりも免疫療法の採用が増加しており、予測期間中に採用が増加すると予測されています。さらに、腫瘍学に使用される新規免疫療法に対する権威主義的な施設からの規制承認の増加も、市場成長をさらに促進すると予想されます。例えば、2021年10月に米国FDAはジェネンテック社のテセントリク（アテゾリズマブ）をNSCLCの治療薬として承認しました。

さらに、がん領域の免疫療法薬の強固な製品パイプラインは、市場の力強い成長の主な促進要因の1つです。例えば、アストラゼネカ社が小細胞肺悪性腫瘍のファーストライン治療薬として開発した（フェーズIII）。免疫腫瘍薬は、生存率の向上と毒性の軽減という有望な結果を示しています。このような臨床試験結果によって、今後数年間は新規治療オプションのイントロダクションが増加すると予想されます。

がん治療への併用療法の採用が増加していることも、免疫療法の需要をさらに高めると予想されます。併用療法は腫瘍微小環境内の複数の経路を標的とするため、免疫療法の効果を高める可能性があります。企業は主に、がん疾患治療のための新規レジメンとして標的治療薬の開発に重点を置いています。

免疫療法のイントロダクションは、乳がん、脳腫瘍、膀胱がん、リンパ腫などの悪性腫瘍の治療選択肢を支援してきました。しかし、化学療法、放射線療法、外科手術に比べると、この治療法の使用量はごくわずかです。免疫療法は今後数年間、悪性腫瘍の主要な治療戦略として台頭してくると予想されています。がん罹患率の憂慮すべき上昇により、がん治療薬やその他の治療法に関する世界の共同研究が活発化しています。例えば、2020年3月、アステラス製薬とCytomX社は次世代免疫腫瘍治療薬のパイプラインを拡大するために提携しました。この提携は、各社の免疫腫瘍学ポートフォリオの強化に役立っています。

さらに、再発難治性悪性腫瘍に対する新規免疫療法の市場開拓と承認が、がん免疫療法市場の拡大を加速させています。例えば、2022年2月、ジョンソン・エンド・ジョンソンのヤンセン・ファーマシューティカル・カンパニーズは、4ライン以上の治療後の難治性多発性骨髄腫の治療薬としてCARVYKTIを米国FDAから承認されたと発表しました。

がん免疫療法市場レポートハイライト

• モノクローナル抗体の研究開発投資の増加により、モノクローナル抗体分野が2023年に最大の市場シェアを占めました。
• 製品別では、がん細胞溶解ウイルス療法とがんワクチンのサブセグメントが、進行期の悪性腫瘍患者に対する臨床的有用性が高いことから、最も速い速度で成長すると予測されます。
• 用途別では、肺がんが有病率の上昇と免疫療法の採用増加により市場を席巻しています。
• 前立腺がんのサブセグメントは、前立腺がんに対する意識の高まりと製品上市の増加により、最も速いCAGRを記録しそうです。
• 病院・診療所セグメントは、病院における免疫療法薬の需要増加とがん患者の入院増加により、2023年の市場をリードしました。
• アジア太平洋地域は、ヘルスケアの確立が進んでいること、アンメット・メディカル・ニーズが高いことから、予測期間中に最も速い成長が見込まれます。
• 新興国市場の主な企業は、世界市場での足跡を拡大するため、新規治療法の開拓や地域的な拡大に継続的に取り組んでいます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 がん免疫療法市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• がん免疫療法市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 がん免疫療法市場：製品推定・動向分析

• 製品市場シェア、2023年と2030年
• セグメントダッシュボード
• 製品別の世界のがん免疫療法市場の見通し
• 以下の市場規模、予測および動向分析、2018年～2030年
  • モノクローナル抗体
  • 免疫調節剤
  • 腫瘍溶解性ウイルス療法とがんワクチン

第5章 がん免疫療法市場：用途の推定・動向分析

• 用途市場シェア、2023年と2030年
• セグメントダッシュボード
• 用途別の世界のがん免疫療法市場の見通し
• 以下の市場規模、予測および動向分析、2018年～2030年
  • 肺がん
  • 乳がん
  • 結腸直腸がん
  • 黒色腫
  • 前立腺がん
  • 頭頸部がん
  • 卵巣がん
  • 膵臓がん
  • その他

第6章 がん免疫療法市場：分布推定・動向分析

• 流通市場シェア、2023年と2030年
• セグメントダッシュボード
• 分布別の世界のがん免疫療法市場の見通し
• 以下の市場規模、予測および動向分析、2018年～2030年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 がん免疫療法市場：最終用途推定・動向分析

• 流通市場シェア、2023年と2030年
• セグメントダッシュボード
• 最終用途別の世界のがん免疫療法市場の見通し
• 以下の市場規模、予測および動向分析、2018年～2030年
  • 病院・クリニック
  • がん研究センター
  • その他

第8章 がん免疫療法市場：地域推定・動向分析

• 地域市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界の地域市場のスナップショット
• 市場規模と予測トレンド分析、2018年～2030年
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • List of key distributors and channel partners
  • Key customers
  • Key company market share analysis, 2023年
  • Pfizer Inc.
  • AstraZeneca
  • Merck &Co., Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Lilly
  • Johnson &Johnson Services, Inc
  • Immunocore, Ltd

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 4 North America Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 5 North America Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 6 North America Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 7 US Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 8 US Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 9 US Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 10 US Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 11 Canada Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 12 Canada Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 13 Canada Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 14 Canada Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 15 Europe Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 17 Europe Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 18 Europe Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 19 Europe Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 20 Germany Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 21 Germany Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 22 Germany Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 23 Germany Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 24 UK Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 25 UK Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 26 UK Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 27 UK Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 28 France Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 29 France Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 30 France Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 31 France Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 32 Italy Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 33 Italy Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 34 Italy Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 35 Italy Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 36 Spain Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 37 Spain Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 38 Spain Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 39 Spain Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 40 Denmark Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 41 Denmark Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 42 Denmark Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 43 Denmark Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 44 Sweden Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 45 Sweden Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 46 Sweden Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 47 Sweden Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 48 Norway Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 49 Norway Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 50 Norway Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 51 Norway Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 52 Asia Pacific Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
• Table 53 Asia Pacific Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 54 Asia Pacific Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 57 China Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 58 China Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 59 China Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 60 China Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 61 Japan Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 62 Japan Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 63 Japan Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 64 Japan Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 65 India Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 66 India Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 67 India Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 68 India Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 69 South Korea Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 70 South Korea Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 71 South Korea Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 72 South Korea Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 73 Australia Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 74 Australia Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 75 Australia Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 76 Australia Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 77 Thailand Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 78 Thailand Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 79 Thailand Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 80 Thailand Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 81 Latin America Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
• Table 82 Latin America Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 83 Latin America Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 84 Latin America Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 85 Latin America Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 86 Brazil Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 87 Brazil Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 88 Brazil Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 89 Brazil Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 90 Mexico Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 91 Mexico Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 92 Mexico Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 93 Mexico Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 94 Argentina Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 95 Argentina Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 96 Argentina Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 97 Argentina Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 98 MEA Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
• Table 99 MEA Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 100 MEA Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 101 MEA Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 102 MEA Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 103 South Africa Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 104 South Africa Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 105 South Africa Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 106 South Africa Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 111 UAE Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 112 UAE Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 113 UAE Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 114 UAE Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
• Table 115 Kuwait Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
• Table 116 Kuwait Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
• Table 117 Kuwait Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
• Table 118 Kuwait Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Cancer Immunotherapy market: market outlook
• Fig. 14 Cancer Immunotherapy competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Cancer Immunotherapy market driver impact
• Fig. 20 Cancer Immunotherapy market restraint impact
• Fig. 21 Cancer Immunotherapy market strategic initiatives analysis
• Fig. 22 Cancer Immunotherapy market: Product movement analysis
• Fig. 23 Cancer Immunotherapy market: Product outlook and key takeaways
• Fig. 24 Monoclonal Antibodies market estimates and forecast, 2018 - 2030
• Fig. 25 Immunomodulators market estimates and forecast, 2018 - 2030
• Fig. 26 Oncolytic Viral Therapies and Cancer Vaccines market estimates and forecast, 2018 - 2030
• Fig. 27 Cancer Immunotherapy Market: Application movement Analysis
• Fig. 28 Cancer Immunotherapy market: Application outlook and key takeaways
• Fig. 29 Lung Cancer market estimates and forecasts, 2018 - 2030
• Fig. 30 Breast Cancer market estimates and forecasts, 2018 - 2030
• Fig. 31 Colorectal Cancer market estimates and forecasts, 2018 - 2030
• Fig. 32 Melanoma market estimates and forecasts, 2018 - 2030
• Fig. 33 Prostate Cancer market estimates and forecasts, 2018 - 2030
• Fig. 34 Head and Neck Cancer market estimates and forecasts, 2018 - 2030
• Fig. 35 Ovarian Cancer market estimates and forecasts, 2018 - 2030
• Fig. 36 Pancreatic Cancer market estimates and forecasts, 2018 - 2030
• Fig. 37 Others market estimates and forecasts, 2018 - 2030
• Fig. 38 Cancer Immunotherapy market: Distribution movement analysis
• Fig. 39 Cancer Immunotherapy market: Distribution outlook and key takeaways
• Fig. 40 Hospital Pharmacy market estimates and forecasts, 2018 - 2030
• Fig. 41 Retail Pharmacy market estimates and forecasts, 2018 - 2030
• Fig. 42 Online Pharmacy market estimates and forecasts, 2018 - 2030
• Fig. 43 Cancer Immunotherapy market: End Use movement analysis
• Fig. 44 Cancer Immunotherapy market: End Use outlook and key takeaways
• Fig. 45 Hospitals & Clinics market estimates and forecasts, 2018 - 2030
• Fig. 46 Cancer Research Centers market estimates and forecasts, 2018 - 2030
• Fig. 47 Others market estimates and forecasts, 2018 - 2030
• Fig. 48 Global Cancer Immunotherapy market: Regional movement analysis
• Fig. 49 Global Cancer Immunotherapy market: Regional outlook and key takeaways
• Fig. 50 Global Cancer Immunotherapy market share and leading players
• Fig. 51 North America market share and leading players
• Fig. 52 Europe market share and leading players
• Fig. 53 Asia Pacific market share and leading players
• Fig. 54 Latin America market share and leading players
• Fig. 55 Middle East & Africa market share and leading players
• Fig. 56 North America: SWOT
• Fig. 57 Europe SWOT
• Fig. 58 Asia Pacific SWOT
• Fig. 59 Latin America SWOT
• Fig. 60 MEA SWOT
• Fig. 61 North America, by country
• Fig. 62 North America
• Fig. 63 North America market estimates and forecasts, 2018 - 2030
• Fig. 64 U.S.
• Fig. 65 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 66 Canada
• Fig. 67 Canada market estimates and forecasts, 2018 - 2030
• Fig. 68 Europe
• Fig. 69 Europe market estimates and forecasts, 2018 - 2030
• Fig. 70 UK
• Fig. 71 UK market estimates and forecasts, 2018 - 2030
• Fig. 72 Germany
• Fig. 73 Germany market estimates and forecasts, 2018 - 2030
• Fig. 74 France
• Fig. 75 France market estimates and forecasts, 2018 - 2030
• Fig. 76 Italy
• Fig. 77 Italy market estimates and forecasts, 2018 - 2030
• Fig. 78 Spain
• Fig. 79 Spain market estimates and forecasts, 2018 - 2030
• Fig. 80 Denmark
• Fig. 81 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 82 Sweden
• Fig. 83 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 84 Norway
• Fig. 85 Norway market estimates and forecasts, 2018 - 2030
• Fig. 86 Asia Pacific
• Fig. 87 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 88 China
• Fig. 89 China market estimates and forecasts, 2018 - 2030
• Fig. 90 Japan
• Fig. 91 Japan market estimates and forecasts, 2018 - 2030
• Fig. 92 India
• Fig. 93 India market estimates and forecasts, 2018 - 2030
• Fig. 94 Thailand
• Fig. 95 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 96 South Korea
• Fig. 97 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 98 Australia
• Fig. 99 Australia market estimates and forecasts, 2018 - 2030
• Fig. 100 Latin America
• Fig. 101 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 102 Brazil
• Fig. 103 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 104 Mexico
• Fig. 105 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 106 Argentina
• Fig. 107 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 108 Middle East and Africa
• Fig. 109 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 110 South Africa
• Fig. 111 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 112 Saudi Arabia
• Fig. 113 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 114 UAE
• Fig. 115 UAE market estimates and forecasts, 2018 - 2030
• Fig. 116 Kuwait
• Fig. 117 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 118 Market share of key market players- Cancer Immunotherapy market

Cancer Immunotherapy Market Growth & Trends:

The global cancer immunotherapy market size is expected to reach USD 224.30 billion by 2030, registering a CAGR of 8.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising adoption of the immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. For instance, in October 2021, the U.S. FDA approved Tecentriq (atezolizumab), of Genentech, Inc for the treatment of NSCLC.

Moreover, the robust product pipeline of the immunotherapy medicines for oncology is one of the major driving factors for strong growth of the market. For instance, (phase-III), developed by AstraZeneca for the treatment of first-line stage small cell lung malignancy. Immuno-oncology agents have shown promising results with improved survival rates and less toxicity. Such clinical trial results are expected to increase the introduction of novel therapeutic options in the coming years.

Increasing adoption of the combination therapies to treat cancer is further expected to increase demand for the immunotherapy. Combination therapies target multiple pathways within the tumor microenvironment that can potentially increase effectiveness of the immunotherapeutic treatment. Companies are mainly emphasizing development of the targeted treatments as novel regimens for the oncology disorder treatment.

The introduction of immunotherapy has aided the treatment options for the malignancies of breast, brain, bladder, lymphomas, and others. Although the usage of this therapy is minimal as compared to chemotherapy, radiotherapy, and surgery. Immunotherapy is anticipated to emerge as the leading treatment strategy for the malignancies during the next few years. The alarming rise in oncology incidence rates has provoked global collaboration on oncology drugs and other therapies. For instance, in March 2020, Astellas Pharma and CytomX collaborated to expand pipeline of the next-generation Immuno-oncology treatments. This collaboration has helped companies to strengthen their immune-oncology portfolio.

Furthermore, development and approval of the novel immunotherapy treatments for relapsed and refractory malignancies are accelerating the cancer immunotherapy market expansion. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of CARVYKTI from the U.S. FDA for treatment of the refractory multiple myeloma after four or more lines of treatment.

Cancer Immunotherapy Market Report Highlights:

• Monoclonal antibodies segment held the largest market share in 2023 owing to rising investments in the R&D of monoclonal antibodies
• By product, the oncolytic viral therapies & cancer vaccines sub-segment is anticipated to grow at the fastest rate owing to their greater clinical benefit to patients with advanced-stage malignancies
• Based on application, lung cancer dominated the market owing to the rise in prevalence of the disease and increasing adoption of immunotherapy for the treatment
• The prostate cancer sub-segment is likely to register the fastest CAGR due to the increasing awareness about prostate cancer and rising product launch
• The hospitals & clinics segment led the market in 2023 owing to the increasing demand for immunotherapeutic medicines in hospitals and increasing hospitalization of cancer patients
• Asia Pacific is expected to exhibit the fastest growth during the forecast period due to the growing establishment of healthcare, and high unmet medical needs
• Key market players are continuously involved in the development of novel treatments and geographical expansion, in order to expand their footprint in the global market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Distribution
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Application
  • 2.2.3. Distribution
  • 2.2.4. End Use
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cancer Immunotherapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Growing R&D activities by pharmaceutical companies
    • 3.2.1.3. Technological advancements and introduction of novel drugs
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Risk of side effects associated with the treatment
    • 3.2.2.2. High cost of therapy and unfavorable reimbursement scenario
• 3.3. Cancer Immunotherapy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Cancer Immunotherapy Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Cancer Immunotherapy Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Monoclonal Antibodies
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Immunomodulators
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Oncolytic Viral Therapies and Cancer Vaccines
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cancer Immunotherapy Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Cancer Immunotherapy Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Lung Cancer
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Breast Cancer
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Colorectal Cancer
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Melanoma
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Prostate Cancer
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Head and Neck Cancer
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. Ovarian Cancer
    • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.8. Pancreatic Cancer
    • 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.9. Others
    • 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Cancer Immunotherapy Market: Distribution Estimates & Trend Analysis

• 6.1. Distribution Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Cancer Immunotherapy Market by Distribution Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Hospital Pharmacy
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.2. Retail Pharmacy
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Online Pharmacy
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Cancer Immunotherapy Market: End Use Estimates & Trend Analysis

• 7.1. Distribution Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Cancer Immunotherapy Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Hospitals & Clinics
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.4.2. Cancer Research Centers
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Others
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Cancer Immunotherapy Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Mexico
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. Pfizer Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. AstraZeneca
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Merck & Co., Inc
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. F. Hoffmann-La Roche Ltd
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Bristol-Myers Squibb Company
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Novartis AG
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Lilly
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Johnson & Johnson Services, Inc
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Immunocore, Ltd
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives